%0 Journal Article %1 Ande_2005_39 %A Anderson, Mark E %D 2005 %J Pharmacol. Ther. %K 80 AMP-Dependent Action Adenoma, Adjuvant, Adolescent, Adrenergic Adul, Adult, Aged, Aldehydes, Alveolar Analysis Animals, Antineoplastic Arrhythmia, Atrial Atrioventricular Biological, C57BL, Calcium Calcium, Capillaries, Cardiac Cardiomegaly, Cardiomyopathies, Cell Channels, Chemotherapy Chemotherapy, Choristoma, Cohort Combined Computer-Assisted, Congestive, Cyclic Cyclophosphamide, Dacarbazine, Dependent Diagnosis, Differential, Disease Disease, Diseases, Doxorubicin, Enzymologic, Expression Extramural, Failure, Female, Fibrillation, Flecainide, Gastrointestinal Gene Genetic Genetic, Heart Heart, Hematoma, Hemorrhage, Homeostasis, Humans, Ifosfamide, Image Inbred Isoprostanes, Isoproterenol, Kinase, Kinases, Knockout, L-Type, Line, Lipid Long Low, Male, Mediastinal Mesna, Node, Output, Part, Peroxidation, Potentials, Predisposition Processing, Protein Protocols, QT Regulation, Screening, Soft Studies, Susceptibility, Syndrome, Variance, and beta-Antagonists, of over, to {C}a$^{2+}$-Calmodulin %N 1 %P 39--55 %R 10.1016/j.pharmthera.2004.11.002 %T Calmodulin kinase signaling in heart: an intriguing candidate target for therapy of myocardial dysfunction and arrhythmias. %U http://dx.doi.org/10.1016/j.pharmthera.2004.11.002 %V 106 %X The multifunctional Ca$^2+$/calmodulin (CaM)-dependent protein kinase II (CaMKII) has emerged as a proarrhythmic and procardiomyopathic signal in a wide range of structural heart diseases. This review discusses CaMKII structure and function and recent evidence implicating CaMKII inhibition as a potential strategy for treating myocardial dysfunction and arrhythmias in the setting of structural heart disease.

@article{Ande_2005_39, abstract = {The multifunctional {C}a$^{2+}$/calmodulin (CaM)-dependent protein kinase II (CaMKII) has emerged as a proarrhythmic and procardiomyopathic signal in a wide range of structural heart diseases. This review discusses CaMKII structure and function and recent evidence implicating CaMKII inhibition as a potential strategy for treating myocardial dysfunction and arrhythmias in the setting of structural heart disease.}, added-at = {2009-06-03T11:20:58.000+0200}, author = {Anderson, Mark E}, biburl = {https://www.bibsonomy.org/bibtex/27170fdd28ee17c0dc0529075a31e7bf4/hake}, description = {The whole bibliography file I use.}, doi = {10.1016/j.pharmthera.2004.11.002}, file = {Ande_2005_39.pdf:Ande_2005_39.pdf:PDF}, interhash = {6ea79f10706773291ee5d6bd7ef4a3c2}, intrahash = {7170fdd28ee17c0dc0529075a31e7bf4}, journal = {Pharmacol. Ther.}, key = 287, keywords = {80 AMP-Dependent Action Adenoma, Adjuvant, Adolescent, Adrenergic Adul, Adult, Aged, Aldehydes, Alveolar Analysis Animals, Antineoplastic Arrhythmia, Atrial Atrioventricular Biological, C57BL, Calcium Calcium, Capillaries, Cardiac Cardiomegaly, Cardiomyopathies, Cell Channels, Chemotherapy Chemotherapy, Choristoma, Cohort Combined Computer-Assisted, Congestive, Cyclic Cyclophosphamide, Dacarbazine, Dependent Diagnosis, Differential, Disease Disease, Diseases, Doxorubicin, Enzymologic, Expression Extramural, Failure, Female, Fibrillation, Flecainide, Gastrointestinal Gene Genetic Genetic, Heart Heart, Hematoma, Hemorrhage, Homeostasis, Humans, Ifosfamide, Image Inbred Isoprostanes, Isoproterenol, Kinase, Kinases, Knockout, L-Type, Line, Lipid Long Low, Male, Mediastinal Mesna, Node, Output, Part, Peroxidation, Potentials, Predisposition Processing, Protein Protocols, QT Regulation, Screening, Soft Studies, Susceptibility, Syndrome, Variance, and beta-Antagonists, of over, to {C}a$^{2+}$-Calmodulin}, month = Apr, number = 1, pages = {39--55}, pdf = {Ande_2005_39.pdf}, pii = {S0163-7258(04)00197-4}, pmid = {15781121}, timestamp = {2009-06-03T11:21:00.000+0200}, title = {Calmodulin kinase signaling in heart: an intriguing candidate target for therapy of myocardial dysfunction and arrhythmias.}, url = {http://dx.doi.org/10.1016/j.pharmthera.2004.11.002}, volume = 106, year = 2005 }